Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer biosimilar to...

    Pfizer biosimilar to Roche Herceptin wins USFDA nod

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-12T09:45:08+05:30  |  Updated On 12 March 2019 9:45 AM IST
    Pfizer biosimilar to Roche Herceptin wins USFDA nod

    The approval for Pfizer comes nearly a year after the agency declined to approve the drug, Trazimera, and sought additional technical information. The USFDA had declined to approve Pfizer’s biosimilar of Herceptin in April.


    New Delhi: The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.


    The approval for Pfizer comes nearly a year after the agency declined to approve the drug, Trazimera, and sought additional technical information. The USFDA had declined to approve Pfizer’s biosimilar of Herceptin in April.


    Since then, the FDA has approved a biosimilar to Herceptin from Celltrion Inc, and one developed by Samsung Bioepis Co Ltd, a joint venture between Samsung Biologics and Biogen Inc.


    Medical Dialogues had earlier reported that USFDA had approved a biosimilar to Roche Holding AG’s blockbuster breast cancer treatment, Herceptin. The biosimilar, Ontruzant, is sold by Merck Sharp & Dohme Corp, a unit of Merck & Co Inc, and is developed by Samsung Bioepis Co Ltd, which is a joint venture between Samsung BioLogics and Biogen Inc.


    Also Read: Samsung Bioepis biosimilar to Roche Herceptin wins FDA nod


    The FDA has also approved Mylan's biosimilar of Herceptin.


    Herceptin is one of Roche's top drugs and brought in sales of 6.98 billion Swiss francs in 2018. Herceptin is one of the world’s most successful antibody drugs and has been a mainstay of Roche profits for many years. However, sales have been hit by rising competition from cheaper biosimilars, particularly in Europe.


    Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision. Their similar versions are called biosimilars, instead of generics.


    Pfizer is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.


    Also Read: No selection process-ICMR, Pfizer collaboration on AMR project draws Objections from industry

    Bioepis CoBiogen Incbiosimilarbreast cancerBreast Cancer Managementcancercancer drugcancer medicinecancer treatmentCelltrion Incdrug TrazimeraFDA approvalgenericHerceptinmedicineMylanPfizerRocheRoche AGSamsung BioLogicstreatmentUSFDA
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok